Coping With the Loss of a Pet

Reverend Kaleel Sakakeeny, a pet grief counselor and CEO of Animal Talks Inc., discusses the different stages of grieving that pet owners may experience, how an animal’s death can compare to that of a human in our lives, what can happen if we do not grieve the death of a pet properly, and how to decide if one-on-one grief counseling is right for you. For more information visit www.animaltalksinc.com

Read More

BREATHER ® Device Helping Patients Worldwide Either Recover or Improve the Performance of Their Lungs & Heart as Well as Reduce Stress and Anxiety

Mark Carbone, CEO of PN Medical, a company helping people worldwide improve their respiratory health and performance discusses Respiratory Muscle Training (RMT) and The BREATHER ®, the first drug-free device for those who suffer from shortness of breath, speech and swallow difficulties, and other complications resulting from respiratory muscle weakness. There has been increasing evidence that RMT can help reduce stress, anxiety, and sleeplessness. The company also has also shown that The BREATHER ® device has helped patients strengthen their cardiac system and circulation, thereby reducing their blood pressure and improving sleep.

Read More

The Importance of Diversity and Inclusion in Healthcare

Juan Mejia, who serves as the President of NewYork-Presbyterian’s Brooklyn Methodist Hospital and as the executive lead of the system’s LGBTQ+ task force, discusses the impact of change a C-suite leader has within both the hospital and the surrounding communities, how senior leaders roles have changed with technological evolution and digitalization, and how New York-Presbyterian has cultivated a community that celebrates diversity and understanding for patients, their families, and for NYP’s workforce.

Read More

FDA Approves Label Update to Include Additional Data for Otezla ® (apremilast)

Dr. Lyn Guenther, MD, FRCPC, Professor of Dermatology at Western University in London Ontario Canada discusses the FDA approval for a label update  for  Otezla ® (apremilast)  to include results from the Phase 3 DISCREET trial, which assessed the efficacy and safety of Otezla in patients with moderate-to-severe plaque psoriasis and with moderate-to-severe genital psoriasis (PsO).

Read More

Latest AHA/ACC Guidelines Recommend XARELTO ® for the Treatment of Patients with CAD

Dr. Avery Ince, MD, PhD, Vice President, Medical Affairs, Cardiovascular & Metabolism at the Janssen Pharmaceutical Companies of Johnson & Johnson, discusses the American Heart Association (AHA) and the American College of Cardiology’s (ACC) release of their 2023 Guideline on the Management of Patients With Chronic Coronary Disease, including Coronary Artery Disease (CAD). The updated guidelines provide clear guidance on how adding XARELTO ®, the only approved treatment of its class for CAD, to commonly used antiplatelet aspirin can help reduce the risk of major CV events for adult patients with CAD.

Read More